Compare Eli Lilly And Co (LLY) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs ON Holding AG — how do they compare? Eli Lilly And Co trades at $1,159.57 (market cap $1.02T), while ON Holding AG trades at $37.36 (market cap $12.55B). The key difference: Eli Lilly And Co is far larger — about 81.3× ON Holding AG's market cap, and Eli Lilly And Co pays a 0.6% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| LLY | ONON | |
|---|---|---|
Market Cap | $1.02T | $12.55B |
Sector | Health | Technology |
52-Week High | $1.24K | $53.21 |
52-Week Low | $625.65 | $31.88 |
Enterprise Value | $1.06T | $11.87B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
ONON trades at $37.65, up 1.21% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 63.88% gross margin and has beaten earnings estimates for three consecutive quarters. Revenue reached $3.01B in 2025, with net income of $203.70M. Analyst sentiment is overwhelmingly positive, with 76.92% recommending Buy.
The outlook remains favorable due to consistent earnings beats and projected revenue growth to $3.1B in 2026. Risks include high valuation multiples like a P/E of 40.14 and competitive pressures. The consensus price target of $47.33 suggests 25.7% upside, but investors should monitor execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
